A previous version of this article incorrectly said that skin cancer is diagnosed in 20 percent of Americans each year. It should have said that skin cancer is diagnosed in 20 percent of Americans in their lifetime. The article has been corrected.
2024
Does Dabrafenib-Trametinib Improve Overall Survival in Melanoma?
In patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib reduces the risk for death by 20% compared with placebo, though the overall survival benefit does not reach statistical significance.
Iovance submits EU marketing authorization for lifileucel for advanced melanoma
Iovance Biotherapeutics has submitted a marketing authorization application to the European Medicines Agency for lifileucel to treat advanced melanoma, the company announced in a press release.
High fail rate for melanoma self-checks increasing cancer risk, new study finds
Australians are unable to recognize malignant melanomas on their own skin, calling into question the effectiveness of national self-detection guidelines, according to new Southern Cross University research.